{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:11:34Z","timestamp":1793326294449,"version":"4.5.0"},"reference-count":44,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019016","name":"Assessment of SpondyloArthritis international Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Using randomised controlled trial (RCT) data, this study evaluated the measurement properties of selected instruments to assess peripheral arthritis in axial and peripheral spondyloarthritis (axSpA\/pSpA) and to inform selection of the best-performing instrument.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible studies were RCTs in axSpA or pSpA with individual patient data available to calculate Patient Global Assessment (PGA), swollen\/tender joint counts (44 or 66\/68 joints), C reactive protein, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Axial Spondyloarthritis Disease Activity Score, Disease Activity Index for Psoriatic Arthritis\/Disease Activity in Psoriatic Arthritis with 44 joint count (DAPSA44) and 44-joint Disease Activity Score at baseline and timing of primary endpoint. In axSpA, analyses were restricted to patients with peripheral arthritis at baseline. Measurement properties assessed included construct validity, test\u2013retest reliability, longitudinal construct validity, trial discrimination and thresholds of meaning. Risk of bias (RoB) was evaluated and evidence was synthesised using Outcome Measures in Rheumatology-based GREEN\/AMBER\/RED ratings (low\/uncertain\/high RoB and good\/adequate\/poor performance, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>13 RCTs were included (10 axSpA and 3 pSpA). In axSpA trials, 25\u201351% of patients had peripheral arthritis at baseline (median swollen joint count of 44 joints (SJC44) across studies: 2\u20133); in pSpA trials, median SJC44 ranged 2\u20135. In axSpA, construct validity and thresholds of meaning were rated AMBER\/GREEN for all instruments, while test\u2013retest reliability was RED only for PGA. Responsiveness was consistently GREEN. Clinical trial discrimination was RED for single-item instruments but consistently GREEN for composite scores. In pSpA, most instruments showed AMBER\/GREEN performance, although SJC44 demonstrated RED discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first comprehensive, trial-based evaluation of measurement properties for instruments assessing peripheral arthritis activity in axSpA and pSpA. Composite scores, such as BASDAI, ASDAS and DAPSA44, generally demonstrated more robust performance than single-item instruments, expanding the evidence base for the final instrument-selection phase.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-007207","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:30:35Z","timestamp":1790343035000},"page":"e007207","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative analysis of instruments measuring peripheral arthritis activity in Spondyloarthritis: a measurement properties study in 13 RCTs"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-0416","authenticated-orcid":false,"given":"Dafne","family":"Capelusnik","sequence":"first","affiliation":[{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"},{"name":"Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-5837","authenticated-orcid":false,"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[{"name":"Rheumatology, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"Maimonides Biomedical Research Institute of Cordoba, University of Cordoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"additional","affiliation":[{"name":"Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"},{"name":"Department of Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Providence Swedish Medical Center; and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1986","authenticated-orcid":false,"given":"Anna","family":"Molto","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Bichat Hospital, Paris, France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, INSERM, INRAE, Centre for Research in Epidemiology and Statistics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092506301727000_12.3.e007207.1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"2026092506301727000_12.3.e007207.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2026092506301727000_12.3.e007207.3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.berh.2019.02.010","article-title":"Peripheral spondyloarthritis: concept, diagnosis and treatment","volume":"32","author":"Molto","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026092506301727000_12.3.e007207.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1927-6","article-title":"Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort","volume":"21","author":"L\u00f3pez-Medina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026092506301727000_12.3.e007207.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854"},{"key":"2026092506301727000_12.3.e007207.6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2021.04.007","article-title":"Peripheral arthritis and higher disease activity lead to more functional impairment in axial spondyloarthritis: longitudinal analysis from ESPAXIA","volume":"51","author":"Capelusnik","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026092506301727000_12.3.e007207.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181331"},{"key":"2026092506301727000_12.3.e007207.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2026092506301727000_12.3.e007207.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2026092506301727000_12.3.e007207.10","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320504"},{"key":"2026092506301727000_12.3.e007207.11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005525","article-title":"Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial","volume":"11","author":"L\u00f3pez-Medina","year":"2025","journal-title":"RMD Open"},{"key":"2026092506301727000_12.3.e007207.12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ard.2025.02.011","article-title":"Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study","volume":"84","author":"Capelusnik","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026092506301727000_12.3.e007207.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207235"},{"key":"2026092506301727000_12.3.e007207.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210075"},{"key":"2026092506301727000_12.3.e007207.15","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag042","article-title":"Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological\/targeted synthetic DMARDs","volume":"65","author":"Webers","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"2026092506301727000_12.3.e007207.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2026-006900","article-title":"Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review","volume":"12","author":"Capelusnik","year":"2026","journal-title":"RMD Open"},{"key":"2026092506301727000_12.3.e007207.17","unstructured":"Beaton DMG , Shea B , Tugwell P , eds. The OMERACT handbook version 2.1 26. 2021."},{"key":"2026092506301727000_12.3.e007207.18","unstructured":"Vivli . Center for global clinical research data. n.d. Available: https:\/\/vivli.org"},{"key":"2026092506301727000_12.3.e007207.19","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2026092506301727000_12.3.e007207.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2026092506301727000_12.3.e007207.21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ard.2025.06.265","article-title":"POS0910 Development and validation of a disease activity index for psoriatic arthritis based on 44 joints: DAPSA44","volume":"84","author":"Capelusnik","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026092506301727000_12.3.e007207.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.11.916"},{"key":"2026092506301727000_12.3.e007207.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.08.011"},{"key":"2026092506301727000_12.3.e007207.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151244"},{"key":"2026092506301727000_12.3.e007207.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023028"},{"key":"2026092506301727000_12.3.e007207.26","doi-asserted-by":"publisher","DOI":"10.4236\/jwarp.2015.77047"},{"key":"2026092506301727000_12.3.e007207.27","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences.2nd edn. Routledge, 1988."},{"key":"2026092506301727000_12.3.e007207.28","doi-asserted-by":"crossref","first-page":"152664","DOI":"10.1016\/j.semarthrit.2025.152664","article-title":"Summary of findings tables for measurement property reviews: the evolution and application of OMERACT\u2019s summary of measurement properties (SOMP) table","volume":"72","author":"Beaton","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026092506301727000_12.3.e007207.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216999"},{"key":"2026092506301727000_12.3.e007207.30","first-page":"S","article-title":"Scores for all seasons: SDAI and CDAI","volume":"32","author":"Smolen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026092506301727000_12.3.e007207.31","unstructured":"Lopez Medina CD , Heijde D , Smolen JS , et al . Psoriatic arthritis based on 44 joints (DAPSA44) using data from phase 3 clinical trials of bimekizumab in psoriatic arthritis. EULAR, 2026."},{"key":"2026092506301727000_12.3.e007207.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2026092506301727000_12.3.e007207.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2026092506301727000_12.3.e007207.34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026092506301727000_12.3.e007207.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"2026092506301727000_12.3.e007207.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2026092506301727000_12.3.e007207.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2026092506301727000_12.3.e007207.38","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026092506301727000_12.3.e007207.39","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026092506301727000_12.3.e007207.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"2026092506301727000_12.3.e007207.41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026092506301727000_12.3.e007207.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202245"},{"key":"2026092506301727000_12.3.e007207.43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026092506301727000_12.3.e007207.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210775"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-007207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:30:39Z","timestamp":1790343039000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-007207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-007207"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-007207","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}